Inmed Pharmaceuticals INC Form 4 insider transactions

InMed Pharmaceuticals' Senior VP of Pre-Clinical Research and Development, Eric C. Hsu, was granted 2,750 stock options on December 20, 2024.

InMed Pharmaceuticals CEO Eric Adams was granted 6,250 stock options on December 20, 2024, which vest monthly over 36 months.

Director Bryan Baldasare of InMed Pharmaceuticals acquired 550 stock options at an exercise price of $4.14, vesting in one year.

Director Andrew Hull reports the grant of stock options in InMed Pharmaceuticals, exercisable for 550 common shares, as well as reflecting a reverse stock split.

Alexandra Diane Janet Mancini, a consultant for InMed Pharmaceuticals, reported selling 240 shares of common stock on July 31, 2024.

Michael Woudenberg, Chief Operating Officer of InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.

Eric C. Hsu, Sr. VP of Pre-Clinical Research and Development at InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.

Eric A. Adams, President and CEO of InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.

Alexandra Diane Janet Mancini, Sr VP of Clinical and Regulatory Affairs at InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.

Director Andrew Hull of InMed Pharmaceuticals Inc. reports the conversion of stock options into common shares.

Eric C. Hsu, Sr. VP at InMed Pharmaceuticals, reports the conversion of employee stock options into common shares.

Alexandra Diane Janet Mancini, Senior VP of Clinical and Regulatory Affairs at InMed Pharmaceuticals, reports converting employee stock options into common shares.